This therapeutic concept targets stress granule (SG) dynamics to prevent the pathological persistence of these membrane-less organelles in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and related neurodegenerative diseases. Stress granules are transient cytoplasmic aggregates formed via liquid-liquid phase separation (LLPS) to protect mRNA during cellular stress. In ALS/FTD, mutations in proteins like TDP-43, FUS, C9orf72, and Ataxin-2 cause SG persistence, leading to toxic gain-of-function and sequestration of essential RNA-binding proteins.
| Evidence Type | Source | Key Finding | Relevance |
|---|---|---|---|
| SG/ALS | Nat Neurosci 2014, Wolfe JL et al. | TDP-43 and FUS are key SG components; mutations alter SG dynamics | High |
| SG/persistence | Nat Neurosci 2017, Mateju D et al. | ALS-causing mutations impair SG disassembly, causing persistence | High |
| ATXN2/SG | Neuron 2015, Murakami T et al. | ALS-linked ATXN2 expansions enhance SG formation | High |
| SG/mechanism | Trends Neurosci 2019, Gao FB et al. | SG persistence sequesters essential RBPs, disrupts translation | High |
| ATXN2/SG | Nat Neurosci 2023, Book AJ et al. | ATXN2 regulates SG assembly/disassembly cycle | High |
| Evidence Type | Source | Key Finding | Relevance |
|---|---|---|---|
| Biomarker | Acta Neuropathol 2022, Bhardwaj A et al. | SG markers detectable in patient CSF | Medium |
| Imaging | Brain 2023, Hall J et al. | SG-like aggregates in patient motor cortex | Medium |
| Genetic | Neurology 2022, Gruzman A et al. | ATXN2 intermediate repeats modify ALS progression | High |
| Target | Function | Therapeutic Approach | Status |
|---|---|---|---|
| G3BP1 | Core SG nucleator | Small molecule disruptors | Preclinical |
| ATXN2 | SG assembly modulator | ASO to reduce expression | Preclinical |
| TIA1 | SG structural protein | Peptide inhibitors | Preclinical |
| Caprin1 | SG scaffold | Gene therapy | Discovery |
| DDX3X | RNA helicase | Small molecule modulators | Discovery |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | Stress granule modulation is a first-in-class approach; addresses upstream of TDP-43 aggregation |
| Mechanistic Rationale | 9 | Direct genetic validation from C9orf72, ATXN2, TDP-43, FUS mutations; all affect SG dynamics |
| Root-Cause Coverage | 8 | Targets the upstream aggregation trigger (persistent SGs) rather than downstream aggregates |
| Delivery Feasibility | 7 | ASO delivery to CNS established; small molecules require blood-brain barrier optimization |
| Safety Plausibility | 7 | Transient SG formation is protective; complete blockade would require careful dosing |
| Combinability | 8 | Synergistic with TDP-43 splicing modulation, autophagy enhancers, and anti-aggregation approaches |
| Biomarker Availability | 7 | CSF SG markers, p-tau217 for patient selection; requires validation |
| De-risking Path | 7 | ASO platform validated in ALS (tofersen); SG modulators can use similar regulatory pathway |
| Multi-disease Potential | 8 | SG dysfunction in ALS, FTD, AD, PD, HD — broad applicability |
| Patient Impact | 8 | Addresses fundamental mechanism in majority of ALS/FTD cases |
| Total | 77/100 |
| Disease | Coverage Score | Rationale |
|---|---|---|
| ALS | 10 | Core pathology — C9orf72, TDP-43, FUS, ATXN2 all converge on SG dysfunction |
| FTD | 9 | 50% of FTD has TDP-43 pathology; SG dysfunction is upstream trigger |
| PD | 6 | Alpha-synuclein may interact with SG components; emerging evidence |
| AD | 5 | TDP-43 co-pathology common in AD; SG role under investigation |
| HD | 5 | Mutant huntingtin sequesters SG proteins; potential secondary mechanism |
| Aging | 7 | SG dynamics decline with age; age is primary risk factor |
| CBS | 5 | 4R-tau may intersect with SG pathways |
| MSA | 5 | Alpha-synuclein pathology intersects with SG mechanisms |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| SG blockade is toxic | Medium | High | Use partial modulators, not complete blockers |
| Insufficient BBB penetration | High | Medium | Use ASO delivery or focused ultrasound |
| Patient heterogeneity | Medium | Medium | Biomarker-driven patient selection |
| Limited efficacy alone | Medium | Medium | Combine with TDP-43 ASO or autophagy enhancers |
Murakami T, et al. ALS/FTD mutations in Ataxin-2 induce stress granule formation. Neuron. 2015. ↩︎